Please login to the form below

Not currently logged in

inVentiv Health boosts London digital team

Appoints Emma D’Arcy as head of participatory medicine

inVentiv Health Emma D'ArcyinVentiv Health has appointed Emma D'Arcy as head of participatory medicine within its London Digital and Innovation team.

The firm's new participatory medicine function is centred around a model of care that promotes healthcare professionals and patients working in full partnership, using contemporary communications channels to increase patient participation in healthcare decisions.

In her new role D'Arcy, a medical biochemist and writer, will provide enhanced patient-centric perspectives across the clinical, commercial and consulting services firm's entire organisation.

Nick Bartlett, inVentiv's London-based head of digital for Europe, said: “Emma's passion for championing the patient and her fluency in digital and social media will give our healthcare clients a completely unique perspective.

“Her expertise will enhance our ability to deliver compelling, measurable programmes that make a difference for the patients our clients serve. We're thrilled to have her on board.”

D'Arcy moves to inVentiv from Complete Digital, which she joined in 2010 as senior healthcare digital consultant, and prior to that spent five years as a freelance consultant, having previously held roles with Wells Healthcare, Gardiner Caldwell and Adis International.

She is the most recent senior digital healthcare professional to join inVentiv's Digital and Innovation unit, following the recent arrivals of Duncan Arbour as European head of digital strategy and Alex Brock as head of research and insight.

30th September 2013

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge